0001104659-21-123185.txt : 20211005
0001104659-21-123185.hdr.sgml : 20211005
20211005170111
ACCESSION NUMBER: 0001104659-21-123185
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211001
FILED AS OF DATE: 20211005
DATE AS OF CHANGE: 20211005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Korbel Gregory Alan
CENTRAL INDEX KEY: 0001789032
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 211307535
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
tm2129205-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-10-01
0
0001781983
Aprea Therapeutics, Inc.
APRE
0001789032
Korbel Gregory Alan
535 BOYLSTON STREET
BOSTON
MA
02116
0
1
0
0
SVP, Chief Business Officer
Common Stock
2021-10-01
4
M
0
27500
0.92
A
44667
D
Common Stock
2021-10-01
4
S
0
27500
4.89
D
17167
D
Stock Option (right to Buy)
0.92
2021-10-01
4
M
0
27500
0
D
2026-09-14
Common Stock
27500
25245
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option was granted on September 14, 2016 and is fully exercisable.
/s/ Scott M. Coiante, attorney-in-fact
2021-10-05